---
title: Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells
nct_id: NCT03279796
overall_status: UNKNOWN
phase: PHASE2
sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
study_type: INTERVENTIONAL
primary_condition: Rotator Cuff Tear
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03279796.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03279796"
ct_last_update_post_date: 2018-04-26
last_seen_at: "2026-05-12T07:00:09.614Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells

**Official Title:** Autologous Adipose-derived Mesenchymal Stem Cells in the Treatment of Tendon Disease: a Randomized Controlled Trial

**NCT ID:** [NCT03279796](https://clinicaltrials.gov/study/NCT03279796)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Collaborators:** Zhejiang Xingyue Biotechnology Co., Ltd.
- **Conditions:** Rotator Cuff Tear, Lateral Epicondylitis
- **Start Date:** 2018-10-01
- **Completion Date:** 2021-12-31
- **CT.gov Last Update:** 2018-04-26

## Brief Summary

This study was a single-center, randomized, single-blind clinical trial. We plan to include 100 patients who met exclusion criteria of rotator cuff and lateral epicondylosis (tennis elbow) respectively by MRT or ultrasonography. The patients will be randomly divided into two groups. Adipose mesenchymal stem cells will be isolated from adipose tissue, cultured and then transplanted back to the tendon injury site by multiple point injection. 1\*10\^6 cells as an unit. Patients in the experiment group will be injected into an unit of adipose mesenchymal stem cells (1\*10\^6/10kg) while the control group received the same dose compound betamethasone injection. Follow up visit for all patients will occur at 1，3，6 and 12 months after the first injection. Clinical quantitative assessment will measure by the visual analogue scale(VAS). The secondary outcomes are the constant-murley score(CMS) and the rating scale of the American shoulder and elbow surgeons(ASES) and the disability of arm shoulder and hand(DASH). The objective evaluation methods is that the examination of MRI or ultrasound were accomplished before the first injection and at 6 and 12 months afterwards.

## Detailed Description

All injection will be done under ultrasound guidance.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 90 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. clinically diagnosed as rotator cuff tear or lateral epicondylitis (tennis elbow);
2. symptom duration is over 3 months, non-steroidal drug treatment , rehabilitation treatment and other conservative treatment is invalid;
3. patient that can understand the clinical trials and signed the informed consent.

Exclusion Criteria:

1. patient that underwent other injection treatment within 6 weeks
2. some associated diseases (such as arthritis, synovitis, entrapment of related nerve, radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis, pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue)
3. patient that enrolled other clinical trials within 3 months
4. history of drug/alcohol addiction, habitual smoker
```

## Arms

- **Autologous adipose-derived MSCs** (EXPERIMENTAL) — The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
- **Compound betamethasone** (ACTIVE_COMPARATOR) — 1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.

## Interventions

- **Autologous adipose-derived MSCs** (BIOLOGICAL) — The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
- **Compound betamethasone** (DRUG) — 1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.

## Primary Outcomes

- **Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks** _(time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention)_ — Pain on activity will be evaluated by VAS

## Secondary Outcomes

- **Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,** _(time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention)_
- **American Shoulder and Elbow Surgeons (ASES) Shoulder Score** _(time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention)_
- **The Disabilities of the Arm, Shoulder and Hand(DASH) Score** _(time frame: Baseline, 3 weeks, 6 weeks, 12 weeks after intervention)_
- **Adverse events** _(time frame: From baseline through study completion, an average of 1 year)_

## Locations (1)

- Weiliang Shen, Hangzhou, Zhejiang, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.weiliang shen|hangzhou|zhejiang|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03279796.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03279796*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*